Bajaj Healthcare (NSE: BAJAJHCARE) rallies 16% on Cenobamate approval milestone

Bajaj Healthcare Limited (NSE: BAJAJHCARE) surged more than 16% on June 29 after becoming the first company in India to secure a regulatory committee recommendation to manufacture and market Cenobamate tablets for adults with partial-onset seizures. The shares traded near ₹353 after the rally and closed at ₹351.45 on June 30, leaving the stock about 12% higher over five sessions and 16% above its May-end level. The regulatory breakthrough could move Bajaj Healthcare beyond commodity active pharmaceutical ingredients and towards higher-value central nervous system therapies. The next tests are final regulatory permission, the planned Q2 FY27 commercial launch and evidence that the new product can materially improve revenue and margins.

What does Bajaj Healthcare manufacture, and why is it trying to move beyond commodity pharmaceutical ingredients?

Bajaj Healthcare Limited manufactures active pharmaceutical ingredients, intermediates, finished formulations and nutraceutical products. Its facilities serve customers across India and international markets including Europe, the United States, Australia, the Middle East and South America.

The company’s historical strength has been manufacturing pharmaceutical ingredients and supplying drugmakers rather than building a large branded-medicine business. This provides scale and export opportunities, but traditional active pharmaceutical ingredient markets can be highly competitive, with pricing influenced by Chinese supply, raw-material costs and customer bargaining power.

Bajaj Healthcare is attempting to improve the quality of its revenue by increasing exports, expanding finished formulations and developing differentiated products in central nervous system therapies, oncology and peptides. Its contract development and manufacturing business is also being scaled to reduce dependence on lower-margin domestic ingredient sales.

Cenobamate fits that strategy because Bajaj Healthcare intends to manufacture both the active pharmaceutical ingredient and finished tablets. Internal control of the manufacturing chain could support margins, supply reliability and faster commercial execution compared with a company relying entirely on external suppliers.

However, manufacturing integration does not guarantee pricing power. Cenobamate is already an established medicine outside India, and Bajaj Healthcare’s competitive advantage is its Indian regulatory position and manufacturing capability rather than global ownership of the molecule. Long-term economics will depend on final approval, market access, physician adoption and the number of competing Indian manufacturers that eventually enter the category.

Why did BAJAJHCARE shares jump more than 16% after the Cenobamate recommendation?

The Subject Expert Committee for neurology and psychiatry reviewed Bajaj Healthcare’s Phase 3 clinical-trial report and recommended permission to manufacture and market Cenobamate tablets in six strengths ranging from 12.5 milligrams to 200 milligrams. The committee also recommended that the medicine should be sold on a neurologist’s prescription and asked the company to align its prescribing information with the innovator product.

The recommendation significantly reduced the regulatory risk surrounding a product that has been under development for more than a year. Bajaj Healthcare had previously received permission to conduct the Phase 3 study, making the June decision the clearest indication so far that commercialisation is approaching.

The shares rose from around ₹305 before the announcement to approximately ₹352.65 on June 29, touching an intraday level near ₹353.50. More than 1.5 crore shares traded during the session, compared with far lower normal volumes, showing that the catalyst attracted a broad wave of market participation rather than a thinly traded price spike.

The stock eased only slightly to ₹351.45 on June 30. It remained approximately 36% below its 52-week high of ₹552.60, despite rebounding more than 29% from the 52-week low of ₹272.35. That positioning helps explain the intensity of the response because the regulatory catalyst arrived while the stock was still recovering from a prolonged decline.

The rally should nevertheless be viewed as a repricing of approval probability, not recognition of established Cenobamate earnings. Bajaj Healthcare has not yet disclosed the launch price, potential market share, manufacturing capacity dedicated to the product or expected annual revenue. Those omissions leave substantial uncertainty beneath the first-mover narrative.

How important could Cenobamate become for Bajaj Healthcare’s specialty pharmaceutical strategy?

Cenobamate is an antiseizure medicine used to treat partial-onset seizures in adults. The drug is already approved in major international markets, where it is prescribed for patients whose seizures may remain inadequately controlled by existing therapies.

Bajaj Healthcare’s opportunity lies in bringing the medicine to the Indian market through a locally manufactured active ingredient and finished formulation. A first regulatory recommendation can give the company an early commercial window in which to establish neurologist awareness, distribution and hospital relationships before the market becomes more crowded.

The product may also strengthen Bajaj Healthcare’s credibility as a developer of complex formulations rather than only a contract ingredient supplier. Successful execution could support additional central nervous system products and make the company more attractive to partners seeking Indian manufacturing or commercialisation capabilities.

The investment case should not assume that the entire Indian epilepsy population represents an addressable market. Cenobamate is intended for a defined adult seizure category and is expected to remain prescription controlled. Adoption will depend on clinical positioning, treatment guidelines, neurologist confidence, affordability and how the therapy compares with established antiseizure medicines.

Safety monitoring and prescribing requirements could also affect the pace of uptake. Newer neurological therapies often require gradual dose titration and careful management of interactions or adverse effects. Bajaj Healthcare must therefore execute physician education and pharmacovigilance effectively rather than treating the launch like a conventional generic tablet.

The most meaningful commercial signal will be management’s revenue guidance after final approval. Without information on expected patient numbers, pricing and margin contribution, Cenobamate remains strategically important but financially difficult to value.

What milestones must occur before Bajaj Healthcare can generate Cenobamate revenue?

The Subject Expert Committee recommendation must first be converted into formal permission from India’s drug regulator. Bajaj Healthcare also needs to submit revised prescribing information reflecting the committee’s comments before final regulatory documentation can be completed.

The company previously targeted a Q2 FY27 launch, which places the expected commercial window between July and September 2026. The timeline appears achievable after the favourable recommendation, but the launch remains pending until the necessary manufacturing and marketing permission is issued.

Product manufacturing must then be scaled across six tablet strengths. This increases operational complexity because each strength requires validated production, quality controls, packaging, stability documentation and inventory planning.

The June-quarter results represent the next scheduled financial checkpoint. They are likely to be reported during July or August and should reveal whether export growth, formulation demand and contract manufacturing continued after the stronger FY26 performance.

The company is also expected to advance its application for Suvorexant tablets after completing a bioequivalence study. Suvorexant could provide another central nervous system product, although regulatory filing and commercial launch remain separate milestones.

A smaller corporate event is the planned sale of Bajaj Healthcare’s operational unit at Tarapur to Orchem Products for up to ₹4.05 crore. The transaction is expected to be completed by October 31, 2026. The unit generated only ₹3.31 crore of revenue in the previous financial year, meaning its disposal is more relevant as portfolio rationalisation than as a major source of cash.

Do Bajaj Healthcare’s FY26 results support the market’s renewed growth expectations?

Bajaj Healthcare reported FY26 revenue from operations of ₹611.03 crore, an increase of 12.6% from ₹542.60 crore. Earnings before interest, tax, depreciation and amortisation increased 9.9% to ₹111.95 crore, although the operating margin softened to 18.3% from 18.8%.

The strongest operating signal came from exports. Active pharmaceutical ingredient export revenue rose 51.6% to ₹188.14 crore, supported by demand across Europe, the United Kingdom, Latin America and other regulated markets. Formulation revenue increased 12.6% to ₹103.32 crore.

Domestic ingredient revenue declined 2.2% to ₹319.57 crore, reflecting continued price erosion. That divergence reinforces why the company is directing capital towards exports, formulations, contract development and higher-value therapies.

Profit from continuing operations before exceptional items increased 27.1% to ₹54.56 crore. The stronger underlying profit indicates that export growth and cost control improved operating performance even though the reported bottom line told a less flattering story.

Reported FY26 net profit fell to approximately ₹15.77 crore because the company reversed ₹33.25 crore of previously recognised technical know-how income. The associated Middle Eastern customer had been unable to meet its financial commitment after regulatory delays and regional instability, leading Bajaj Healthcare to cancel the arrangement.

The exceptional reversal matters because it exposes the risk of recognising income before customers complete payment and regulatory obligations. It should not be treated as a recurring operating cost, but investors should not ignore the governance and counterparty questions raised by the episode.

Q1 FY27 must show that underlying earnings growth can continue without another accounting adjustment. The share-price rerating will be easier to sustain if export revenue remains strong, domestic pricing stabilises and the contract manufacturing segment begins making a more visible contribution.

How does the global active pharmaceutical ingredient cycle affect the BAJAJHCARE thesis?

Indian pharmaceutical manufacturers are benefiting from attempts by international drugmakers to diversify supply chains beyond China. Regulated-market customers increasingly want multiple suppliers, local manufacturing resilience and better visibility over quality and delivery.

Bajaj Healthcare’s 51.6% growth in active pharmaceutical ingredient exports suggests that it is capturing part of this opportunity. Its regulatory filings also expanded, with 41 drug master files submitted during the fourth quarter and the cumulative total reaching 110.

Drug master files support future commercial opportunities because they provide regulators and customers with information about manufacturing processes, facilities and product quality. However, filing a drug master file does not guarantee an order. Revenue depends on customer approvals, commercial negotiations and product-level demand.

Domestic conditions remain more difficult. Ingredient manufacturers face pricing pressure from excess capacity, competitive imports and customers seeking annual cost reductions. Raw-material volatility and currency movements can further compress margins when selling prices adjust more slowly than input costs.

Bajaj Healthcare’s strategic answer is to shift towards regulated exports, formulations and differentiated products. Cenobamate may help that transition, but the existing ingredient business will continue to determine a large share of revenue in the near term.

The macro thesis is therefore mixed rather than uniformly bullish. Supply-chain diversification supports exports, while domestic commoditisation limits pricing power. Investors need to see the revenue mix change before assigning the company a durable specialty-pharmaceutical valuation.

Is Bajaj Healthcare’s ₹1,183 crore valuation already pricing in a successful launch?

At ₹351.45 per share, Bajaj Healthcare had a market capitalisation of approximately ₹1,183 crore on June 30. The stock traded at about 75 times reported trailing earnings because FY26 profit was depressed by the ₹33.25 crore exceptional reversal.

That multiple gives an exaggerated picture of the operating valuation. Comparing the market capitalisation with underlying profit from continuing operations before exceptional items of ₹54.56 crore produces a multiple closer to 22 times.

A valuation around 22 times underlying earnings is easier to justify for a company producing double-digit revenue growth, 51.6% export growth and a potentially differentiated central nervous system launch. It is not obviously cheap when the domestic ingredient business remains under pressure and the size of the Cenobamate opportunity is undisclosed.

The balance sheet also changed during FY26. Bajaj Healthcare received ₹52.7 crore through the conversion of warrants into equity shares, strengthening liquidity but increasing the number of shares outstanding. Promoter holding stood near 58.3%, while the latest market capitalisation was based on the enlarged equity base.

The stock remains about 36% below its 52-week high, which creates the appearance of recovery potential. However, the previous high is not automatically a fair-value target because earnings expectations, dilution and market conditions have changed.

Further rerating will probably require one of three outcomes: final Cenobamate approval accompanied by credible launch economics, another quarter of strong export and formulation growth, or evidence that contract manufacturing is becoming a meaningful profit contributor.

Failure to deliver those outcomes could return the stock towards an ingredient-manufacturer valuation. The June rally has reduced the discount created by the earlier sell-off, meaning investors entering after the catalyst have less protection against delays or underwhelming commercial guidance.

Why are retail investors watching BAJAJHCARE, and what could reverse the rally?

Retail interest is centred on the phrase “first in India,” the rapid regulatory progression and the possibility that Cenobamate marks Bajaj Healthcare’s transition into higher-margin specialty medicines. The share-price breakout and unusually heavy volume have brought the ticker onto momentum screens beyond its existing pharmaceutical-investor audience.

Public investor discussion is divided between those treating the regulatory recommendation as a major earnings inflection and those waiting for final approval and commercial details. The more cautious debate focuses on whether Cenobamate can become large enough to materially change a company already generating more than ₹600 crore in annual revenue.

Another concern is that management has not quantified the Indian market opportunity. Without price, volume or margin guidance, investors are relying on the drug’s international clinical profile and Bajaj Healthcare’s first-mover position rather than a disclosed financial model.

The reported Q4 loss may also return to focus once the excitement fades. Although the loss was largely created by an exceptional reversal, it highlights counterparty and accounting risks that remain relevant for a smaller pharmaceutical manufacturer.

Liquidity can intensify volatility. More than 1.5 crore shares traded during the rally, while normal daily volumes had previously been far lower. A large influx of short-term traders can produce additional gains, but it can also accelerate profit-taking if approval is delayed or launch guidance disappoints.

The central investment question is whether Bajaj Healthcare is becoming a differentiated pharmaceutical developer or simply adding one promising formulation to an established ingredient business. Cenobamate has strengthened the first interpretation, but the next two quarters must provide commercial evidence.

Key takeaways for investors watching Bajaj Healthcare after the Cenobamate rally

• Bajaj Healthcare became the first company in India to receive a Subject Expert Committee recommendation to manufacture and market Cenobamate tablets.
• The shares surged more than 16% on June 29 and closed at ₹351.45 on June 30, leaving the stock around 16% higher than its May-end level.
• Final regulatory permission remains pending, while the company has targeted a Q2 FY27 commercial launch.
• FY26 revenue grew 12.6% to ₹611.03 crore, with active pharmaceutical ingredient exports rising 51.6%.
• Underlying profit from continuing operations increased 27.1% to ₹54.56 crore, although reported profit fell because of a ₹33.25 crore exceptional reversal.
• The ₹1,183 crore market valuation represents about 22 times underlying FY26 earnings, but closer to 75 times reported trailing profit.
• The next catalysts are final Cenobamate permission, launch economics, June-quarter earnings and evidence of continued export and formulation growth.